Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.84 |
| ▸ | ERBB2 | P04626 | 10/20 | 0.75 |
| ▸ | GAK | O14976 | 1/20 | 0.68 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.68 |
| ▸ | LYN | P07948 | 1/20 | 0.68 |
| ▸ | RET | P07949 | 1/20 | 0.68 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.68 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.68 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.68 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.68 |
| ▸ | EPHA5 | P54756 | 1/20 | 0.68 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.68 |
| ▸ | EPHA4 | P54764 | 1/20 | 0.68 |
| ▸ | ADK | P55263 | 1/20 | 0.68 |
| ▸ | PTK6 | Q13882 | 1/20 | 0.68 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3121700 | 1.00 | EGFR (0.84) | EGFRERBB2GAKRIPK2LYN | |
| SCHEMBL3955254 | 0.96 | EGFR (0.91) | EGFRERBB2GAKRIPK2LYN | |
| SCHEMBL3129292 | 0.96 | EGFR (0.91) | EGFRERBB2GAKRIPK2LYN | |
| SCHEMBL6604644 | 0.96 | EGFR (0.91) | EGFRERBB2GAKRIPK2LYN | |
| SCHEMBL5756288 | 0.95 | EGFR (0.75) | EGFRERBB2GAKRIPK2LYN | |
| SCHEMBL4082267 | 0.95 | EGFR (0.75) | EGFRERBB2GAKRIPK2LYN | |
| SCHEMBL3133020 | 0.94 | ERBB2 (0.75) | EGFRERBB2GAKRIPK2LYN | |
| SCHEMBL12304864 | 0.94 | ERBB2 (0.75) | EGFRERBB2GAKRIPK2LYN | |
| SCHEMBL3123625 | 0.93 | EGFR (0.72) | EGFRERBB2GAKRIPK2LYN | |
| SCHEMBL3131692 | 0.92 | ERBB2 (0.79) | EGFRERBB2GAKRIPK2LYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312343-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | HENNEQUIN LAURENT FRANCOIS AND | 2009-12-17 | — | — | US | disclosed |
| US-20090312343-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | HENNEQUIN LAURENT FRANCOIS AND | 2009-12-17 | — | — | US | disclosed |
| US-20090312343-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | HENNEQUIN LAURENT FRANCOIS AND | 2009-12-17 | — | — | US | disclosed |
| US-7569577-B2 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2009-08-04 | — | — | US | disclosed |
| US-7569577-B2 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2009-08-04 | — | — | US | disclosed |
| US-7569577-B2 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2009-08-04 | — | — | US | disclosed |
| EP-1667991-B1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-05-14 | — | — | EP | disclosed |
| EP-1667991-B1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-05-14 | — | — | EP | disclosed |
| US-20070043009-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
| US-20070043009-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
| US-20070043009-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | US | disclosed |
| EP-1667991-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | Astrazeneca AB (SE) | 2006-06-14 | — | — | EP | disclosed |
| WO-2005026150-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312343-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ERBB2, ABL1, EGFR | EGFR 3/4885ERBB2 1/4885GAK 112/4885 |
| US-20070043009-A1 | Quinazoline derivatives as tyrosine kinase inhibitors | ERBB2, ABL1, EGFR | EGFR 3/4885ERBB2 1/4885GAK 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.